Pear Therapeutics (PEAR) Tops Q4 EPS by 54c

Pear Therapeutics (NASDAQ: PEAR) reported Q4 EPS of $0.13, $0.54 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.32 million versus the consensus estimate of $1.47 million.

GUIDANCE:

Pear Therapeutics sees FY2022 revenue of $22 million.

For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating